title: [Involvement of dynamic HBeAg quantitation and response during chronic hepatitis B treatment].
abstract: OBJECTIVE
  To observe the changes in quantity of serum HBeAg and the Correlation with response during chronic hepatitis B treatment using interferon-alpha or nucleotside analogue, evaluate the predictive value of dynamic HBeAg quantitation to antiviral response.
  
  
  METHODS
  53 cases treated with interferon-alpha and 70 cases treated with nucleotide analogue for 48 weeks. Used the Electro chemiluminescence immunoassay (ECLIA) to measure the quantity of the serum HBeAg before treatment and 12 weeks, 24 weeks and 48 weeks after treatment, analysis the correlation of dynamic HBeAg quantitation with antiviral response.
  
  
  RESULTS
  After 48 weeks treatment, whether interferon-alpha group or nucleotide analogue group, the complete responser quantity of HBeAg before treatment was no significant correlation compared with non-complete responser (P > 0.05), but at treatment weeks 12 and 24 had correlation with the serum HBeAg level and HBeAg decline degree (P < 0.05), deferent HBeAg titer and HBeAg quantatition decline degree during treatment achieved deferent complete response rate, HBeAg titer lesser than 100 U/ml and HBeAg quantatition decline degree higher than 90% at treatment weeks 24 achieved more complete response rate After 48 weeks treatment.
  
  
  CONCLUSIONS
  During the treatment CHB with interferon-alpha or nucleotside analogue, the dynamic changes in quantity of serum HBeAg has a relationship with response.
authors.affiliation: Department of Infection Diseases, The People's Hospital of Weifang, Shandong 261041, China. xiuyingl@yeah.net
authors.forename: Xiu-Ying
authors.initials: XY
authors.lastname: Lun
mesh_terms: D000328:Adult; D000998:Antiviral Agents / Q000627:therapeutic use*; D005260:Female; D006513:Hepatitis B e Antigens / Q000097:blood*; D006515:Hepatitis B virus / Q000502:physiology*; D019694:Hepatitis B, Chronic / Q000097:blood / Q000188:drug therapy* / Q000821:virology; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009711:Nucleotides / Q000627:therapeutic use; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000998:Antiviral Agents; D006513:Hepatitis B e Antigens; D016898:Interferon-alpha; D009711:Nucleotides